Bluejay Diagnostics, Inc. (BJDX) vs Nexalin Technology, Inc. (NXL)
Bluejay Diagnostics, Inc. and Nexalin Technology, Inc. are both Medical Devices companies. Bluejay Diagnostics, Inc. is the larger, with a market value of $4.3M against $3.6M — 1.2× the size. Nexalin Technology, Inc. has negative trailing earnings, so its P/E is not meaningful; Bluejay Diagnostics, Inc. trades at 1.2×. Bluejay Diagnostics, Inc. has the higher net margin (0.00% vs −4,138.5%) and the higher return on invested capital (0.00% vs −1,108.8%). Across the 13 metrics below, Bluejay Diagnostics, Inc. leads on 10 and Nexalin Technology, Inc. on 3.
Valuation
Profitability
| Metric | BJDX | NXL | Medical Devices median |
|---|---|---|---|
| Gross margin | 0.00% | 86.14% | 56.01% |
| Operating margin | 0.00% | (4,201.66%) | (15.03%) |
| Net margin | 0.00% | (4,138.49%) | (20.40%) |
| Free cash flow margin | 0.00% | (2,917.96%) | (7.24%) |
| Return on equity | (98.89%) | (240.25%) | (15.32%) |
| Return on assets | (81.07%) | (187.89%) | (19.72%) |
| Return on invested capital | 0.00% | (1,108.82%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack